BioNTech and Pfizer Highlight Bispecifics Progress at ASCO, Rick Pazdur Offers Optimism
At the ASCO event, BioNTech and Pfizer shared encouraging developments in lung cancer treatments, while Rick Pazdur expressed optimism regarding FDA perspectives.
Editorial Staff
1 min read
Updated 12 days ago
During the ASCO event on May 30, 2026, BioNTech and Pfizer presented promising data related to bispecific therapies, particularly in the context of lung cancer.
The discussions included new immunotherapy approaches that could potentially change treatment landscapes for patients.
Rick Pazdur, a notable figure at the FDA, shared insights that hinted at a more favorable outlook for future regulatory considerations.